Lantern Pharma Inc. logo

Lantern Pharma Inc. (LTRN)

Market Closed
3 Jun, 20:00
NASDAQ (CM) NASDAQ (CM)
$
3. 4000
-0.34
-9.09%
After Hours
$
3. 44
+0.04 +1.18%
42.23M Market Cap
- P/E Ratio
- Div Yield
191,568 Volume
-2.03 Eps
$ 3.74
Previous Close
Investors:
Add Transaction
Day Range
3.26 3.77
Year Range
1.11 5.744
Want to track LTRN and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Lantern Pharma Inc. (LTRN) Discusses Live Demonstration of withZeta.ai AI Platform for Rare Cancer Drug Discovery Transcript

Lantern Pharma Inc. (LTRN) Discusses Live Demonstration of withZeta.ai AI Platform for Rare Cancer Drug Discovery Transcript

Lantern Pharma Inc. (LTRN) Discusses Live Demonstration of withZeta.ai AI Platform for Rare Cancer Drug Discovery Transcript

Seekingalpha | 1 month ago
Lantern Pharma Inc. (LTRN) Discusses Live Demonstration of withZeta.ai Platform for AI-Driven Oncology Drug Discovery Transcript

Lantern Pharma Inc. (LTRN) Discusses Live Demonstration of withZeta.ai Platform for AI-Driven Oncology Drug Discovery Transcript

Lantern Pharma Inc. (LTRN) Discusses Live Demonstration of withZeta.ai Platform for AI-Driven Oncology Drug Discovery Transcript

Seekingalpha | 1 month ago
Lantern Pharma Inc. (LTRN) Shareholder/Analyst Call Transcript

Lantern Pharma Inc. (LTRN) Shareholder/Analyst Call Transcript

Lantern Pharma Inc. (LTRN) Shareholder/Analyst Call Transcript

Seekingalpha | 1 month ago
Lantern Pharma Inc. (LTRN) Q4 2025 Earnings Call Prepared Remarks Transcript

Lantern Pharma Inc. (LTRN) Q4 2025 Earnings Call Prepared Remarks Transcript

Lantern Pharma Inc. (LTRN) Q4 2025 Earnings Call Prepared Remarks Transcript

Seekingalpha | 2 months ago
Lantern Pharma Inc. (LTRN) Discusses LP-184 Phase 1a Clinical Results and Implications for DNA Damage Repair-Deficient Tumors Transcript

Lantern Pharma Inc. (LTRN) Discusses LP-184 Phase 1a Clinical Results and Implications for DNA Damage Repair-Deficient Tumors Transcript

Lantern Pharma Inc. ( LTRN ) Discusses LP-184 Phase 1a Clinical Results and Implications for DNA Damage Repair-Deficient Tumors November 20, 2025 4:30 PM EST Company Participants Panna Sharma - President, CEO & Director Kishor Bhatia - Chief Scientific Officer & Scientific Consultant Reggie Ewesuedo Conference Call Participants Igor Astsaturov Presentation Panna Sharma President, CEO & Director Okay. Thank you, everyone, for joining us today for our LP-184 clinical trial results webinar.

Seekingalpha | 6 months ago
Lantern Pharma Inc. (LTRN) Q3 2025 Earnings Call Transcript

Lantern Pharma Inc. (LTRN) Q3 2025 Earnings Call Transcript

Lantern Pharma Inc. ( LTRN ) Q3 2025 Earnings Call November 13, 2025 9:00 AM EST Company Participants Panna Sharma - President, CEO & Director David Margrave - CFO & Secretary Presentation Operator Good morning, and welcome to our third quarter 2025 earnings call. As a reminder, this call is being recorded [Operator Instructions].

Seekingalpha | 6 months ago
Lantern Pharma Inc. (LTRN) Q1 2025 Earnings Call Transcript

Lantern Pharma Inc. (LTRN) Q1 2025 Earnings Call Transcript

Lantern Pharma Inc. (NASDAQ:LTRN ) Q1 2025 Earnings Conference Call May 15, 2025 9:00 AM ET Company Participants Panna Sharma - President & CEO David Margrave - CFO Conference Call Participants Operator Good morning, and welcome to our First Quarter 2025 Earnings Call. As a reminder, this call is being recorded, and all attendees are in a listen-only mode.

Seekingalpha | 1 year ago
Lantern Pharma Inc. (LTRN) Q4 2024 Earnings Call Transcript

Lantern Pharma Inc. (LTRN) Q4 2024 Earnings Call Transcript

Lantern Pharma Inc. (NASDAQ:LTRN ) Q4 2024 Earnings Conference Call March 27, 2025 4:30 AM ET Company Participants Panna Sharma - President and CEO David Margrave - Chief Financial Officer Kishor Bhatia - Chief Scientific Officer Conference Call Participants Operator Good afternoon, and welcome to our Fourth Quarter and Year End 2024 Earnings Call. As a reminder, this call is being recorded, and all attendees are in a listen-only mode.

Seekingalpha | 1 year ago
Lantern Pharma Inc. (LTRN) Q3 2024 Earnings Call Transcript

Lantern Pharma Inc. (LTRN) Q3 2024 Earnings Call Transcript

Lantern Pharma Inc. (NASDAQ:LTRN ) Q3 2024 Results Conference Call November 7, 2024 4:30 PM ET Company Participants Panna Sharma - President and CEO David Margrave - Chief Financial Officer Kishor Bhatia - Chief Scientific Officer Operator Good afternoon, and welcome to our Third Quarter 2024 earnings call. As a reminder, this call is being recorded, and all attendees are in a listen-only mode.

Seekingalpha | 1 year ago
Lantern Pharma Inc. (LTRN) Q2 2024 Earnings Call Transcript

Lantern Pharma Inc. (LTRN) Q2 2024 Earnings Call Transcript

Lantern Pharma Inc. (NASDAQ:LTRN ) Q2 2024 Earnings Conference Call August 8, 2024 4:30 PM ET Company Participants Panna Sharma - President and CEO David Margrave - Chief Financial Officer Dr. Reggie Ewesuedo - Vice President, Clinical Development Conference Call Participants John Vandermosten - Zacks Research Operator Good afternoon. And welcome to our Second Quarter 2024 Earnings Call.

Seekingalpha | 1 year ago